Quince Therapeutics, Inc. (QNCX) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $0.00; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $0.00; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $18.03M; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term DebtUSD $0.00; Long-Term Debt, Maturity, Year OneUSD $11.76M; Long-Term Debt, Maturity, Year TwoUSD (m).
Quince Therapeutics, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Fair Value Disclosure USD | Convertible Notes Payable USD | Long-Term Debt, Maturity, Year Three USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $18.03M | (m) | (m) | (m) | (m) | (m) | $18.03M | (m) | (m) |
| 2025-12-31 | (m) | $0.00 | $11.76M | (m) | (m) | $11.76M | (m) | (m) | (m) |
| 2025-09-30 | $17.52M | $0.00 | $11.75M | (m) | $0.00 | $11.75M | $17.52M | (m) | (m) |
| 2025-06-30 | (m) | $16.99M | $11.72M | (m) | $0.00 | $11.72M | $16.99M | (m) | (m) |
| 2025-03-31 | (m) | $15.27M | $10.82M | (m) | $0.00 | $10.82M | $15.27M | (m) | (m) |
| 2024-12-31 | $0.00 | $14.32M | (m) | (m) | (m) | (m) | $14.32M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $0.00 | $10.41M | (m) | $10.41M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $14.90M | $0.00 | $11.19M | $0.00 | $11.19M | $14.90M | (m) | (m) |
| 2024-06-30 | (m) | $13.83M | $0.00 | $10.71M | $0.00 | $10.71M | $13.83M | (m) | (m) |
| 2024-03-31 | (m) | $13.52M | $0.00 | $11.05M | $0.00 | $11.05M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $13.43M | (m) | (m) | (m) | (m) | $13.43M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $0.00 | $0.00 | (m) | $11.05M | (m) | (m) | $11.05M |
| 2022-12-31 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-01-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $8.00M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |